"The landscape of prostate cancer management has evolved significantly over the past 30 years, with [active surveillance], advances in imaging and genetics, and improvements in the treatment of ...

“Patients in the darolutamide arm did not reach first [radiological progression-free survival] median, but at 24 months, 70[.3]% had not progressed vs 52[.1]% in the placebo/ADT arm,” said Fred Saad, ...

“Our findings give patients and doctors valuable insights into what to expect after ADT treatment, helping them make informed decisions about managing side effects and improving long-term outcomes," ...

In August 2024, the FDA granted 510(k) clearance to the HYDROS robotic system, an AI-powered platform designed to enhance the delivery of Aquablation therapy for patients with benign prostatic ...

With this integration, imaging data from the DeepHealth software can be readily imported to the Trinity 3D Ultrasound Platform for prostate fusion biopsy. Koelis has announced a partnership with ...

"The idea is to keep improving these devices," says Ana Lidia Flores-Mireles, PhD. In this video, Ana Lidia Flores-Mireles, PhD, further discusses the reusable intermittent urinary catheter system and ...

"The encouraging results suggest that alternating pazopanib with bevacizumab is a promising treatment regimen for renal cell carcinoma patients in the favorable risk group," says Saby George, MD, FACP ...

Enfortumab vedotin plus pembrolizumab was previously granted a priority review designation from the MHLW. Japan’s Ministry of Health, Labour, and Welfare (MHLW) has approved the combination of ...

"Of those that met the primary end point, they remained free of progression at a median of 31 months and counting," says Nicholas G. Nickols, MD, PhD. In this video, Nicholas G. Nickols, MD, PhD, ...

The recommended phase 2 dose was determined to be rogaratinib at 600 mg in combination with atezolizumab at 1200 mg. “The major problem with immunotherapy was it works great for some patients with ...

"One of the things I think that's really interesting is we're seeing the development of a lot of AI predictive models of who might progress to urosepsis and who might be at higher risk for progression ...

"RPLND is an attractive option for those who prefer to avoid chemotherapy," write Jiping Zeng, MD; Timothy A. Masterson, MD; and Clint Cary, MD, MPH, MBA. Retroperitoneal lymph node dissection (RPLND) ...